Molecule
Interferon beta-1a is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. MedsAcross supplies Interferon beta-1a for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
AVONEX is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. AVONEX is for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Source: US FDA prescribing information
The mechanism of action by which AVONEX exerts its effects in patients with multiple sclerosis is unknown.
Source: US FDA prescribing information
For intramuscular use only. Recommended dose: 30 micrograms once a week. AVONEX may be titrated, starting with 7.5 micrograms for first week, to reduce flu-like symptoms. Increase dose by 7.5 micrograms each week for next 3 weeks until recommended dose of 30 micrograms. See patient instructions for use for complete administration instructions. Perform first injection under the supervision of an appropriately qualified health care professional. Analgesics and/or antipyretics on treatment days may help ameliorate flu-like symptoms
Source: US FDA prescribing information
AVONEX is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, or any other component of the formulation. The formerly available lyophilized vial formulation of AVONEX is contraindicated in patients with a history of hypersensitivity to albumin (human). History of hypersensitivity to natural or recombinant interferon beta, albumin or any other component of the formulation
Source: US FDA prescribing information
Depression, Suicide, and Psychotic Disorders: advise patients to immediately report any symptoms of depression, suicidal ideation, and/or psychosis, consider discontinuation of AVONEX if depression occurs. Hepatic Injury: monitor liver function tests, monitor patients for signs and symptoms of hepatic injury, consider discontinuation of AVONEX if hepatic injury occurs. Injection Site Reactions: Do not administer AVONEX into affected area until fully healed, if multiple lesions occur, change injection site or discontinue AVONEX until healing of skin lesions. Anaphylaxis and Other Allergic-Reactions: Discontinue if occurs. Congestive Heart Failure: monitor patients with pre-existing significant cardiac disease for worsening of cardiac symptoms. Decreased Peripheral Blood Counts: monitor complete blood count.
Source: US FDA prescribing information
The following serious adverse reactions are discussed in more detail in other sections of labeling: Depression, Suicide, and Psychotic Disorders Hepatic Injury Anaphylaxis and Other Allergic-Reactions Injection Site Reactions Including Necrosis Congestive Heart Failure Decreased Peripheral Blood Counts Thrombotic Microangiopathy Pulmonary Arterial Hypertension Seizures Autoimmune Disorders Laboratory Tests The most common adverse reactions (at least 5% more frequent on AVONEX than on placebo) were flu-like symptoms including chills, fever, myalgia, and asthenia.
Source: US FDA prescribing information
Refrigerate AVONEX prefilled syringes and autoinjectors at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. DO NOT FREEZE. Once removed from the refrigerator, allow prefilled syringes and autoinjectors to warm to room temperature (about 30 minutes). Should refrigeration be unavailable, a prefilled syringe or autoinjector may be stored at room temperature up to 25°C (77°F) for a period up to 7 days. Once the product is removed from the refrigerator, it must not be stored above 25°C (77°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
9 presentations of Interferon beta-1a, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Avonex kitIntramuscular Cold chain | Biogen | US FDA | Available on request |
| Avonex 30 mcg/0.5 mL injectionIntramuscular Cold chain | Biogen | US FDA | Available on request |
| Avonex Pen 30 mcg/0.5 mL injectionIntramuscular Cold chain | Biogen | US FDA | Available on request |
| Rebif kitSubcutaneous Cold chain | EMD Serono | US FDA | Available on request |
| Rebif 22 mcg/0.5 mL injectionSubcutaneous Cold chain | EMD Serono | US FDA | Available on request |
| Rebif 44 mcg/0.5 mL injectionSubcutaneous Cold chain | EMD Serono | US FDA | Available on request |
| Rebif Rebidose kitSubcutaneous Cold chain | EMD Serono | US FDA | Available on request |
| Rebif Rebidose 22 mcg/0.5 mL injectionSubcutaneous Cold chain | EMD Serono | US FDA | Available on request |
| Rebif Rebidose 44 mcg/0.5 mL injectionSubcutaneous Cold chain | EMD Serono | US FDA | Available on request |
4 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Interferon beta-1a in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 9 presentations of Interferon beta-1a and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 4 brand names for Interferon beta-1a, including Avonex, Avonex Pen, Rebif, Rebif Rebidose.
Yes. The US FDA first approved Interferon beta-1a on 17 May 1996, according to Drugs@FDA.
Yes. Interferon beta-1a has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Interferon beta-1a must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Interferon beta-1a is classified under ATC code L03AB07 (Interferon beta-1a).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.